Boston Scientific (BSX): A Classic VPA “Hockey Stick” Reversal – When Narrowing Spreads and Absorption Signal the Turn

Boston Scientific (BSX): A Classic VPA “Hockey Stick” Reversal – When Narrowing Spreads and Absorption Signal the Turn

In the world of Volume Price Analysis (VPA), few patterns are as satisfying—or as reliable when read correctly—as the “hockey stick.” This is the extended decline that eventually loses momentum, decelerates into a low with clear evidence of buying absorption, and then turns higher. Boston Scientific Corporation (NYSE: BSX) has delivered a textbook example on the weekly chart in recent months. What makes this setup particularly compelling is the confluence of classical VPA signals, a catalyst from the July 29 earnings release, notable insider buying by the C-suite, and the ongoing need to monitor dark-pool activity to confirm institutional accumulation. This is the kind of chart that rewards patience. Narrowing spreads really do reveal all.

Company Background: A leader in Minimally Invasive MedTech

Boston Scientific, founded in 1979 and headquartered in Marlborough, Massachusetts, develops, manufactures, and markets a broad portfolio of medical devices used in interventional procedures. Its two main segments are Cardiovascular (including cardiology and peripheral interventions) and MedSurg (endoscopy, urology, and neuromodulation). The company is a major player in areas such as electrophysiology (EP), structural heart (notably the WATCHMAN left atrial appendage closure device), pulsed field ablation (FARAPULSE platform), and various endoscopic and urological tools. It treats tens of millions of patients annually across more than 120 countries and invests heavily in R&D. Long-term secular tailwinds—ageing populations, the shift toward less-invasive procedures, and innovation in cardiac and neuromodulation therapies—remain intact. Yet even strong companies can experience sharp share-price corrections when growth expectations are reset.

Why Boston Scientific Fell So Far

BSX reached an all-time high near $109.50 in September 2025. From there, the stock endured a prolonged and severe decline of roughly 50–60%, eventually finding support in the low-$40s to mid-$40s range by mid-2026. The primary drivers were successive reductions in full-year 2026 guidance. After delivering solid results, management repeatedly tempered organic revenue growth expectations—initially guided in the low double digits, then lowered in stages to a mid-single-digit range (most recently 5–6% organic). Key pressure points included:

• Flattening U.S. sales of the WATCHMAN franchise, attributed in part to physician workflow constraints and a shift toward concomitant procedures rather than standalone implants.
• Softening trends and increased competition in electrophysiology.
• Broader concerns about growth deceleration in certain high-profile categories.

These guidance cuts triggered multiple waves of analyst target reductions and a re-rating of the multiple. Even when quarterly results beat estimates, the forward outlook often overshadowed the beats, creating a classic “sell the news / sell the guidance” environment. By the time the stock approached its lows, sentiment had become extremely cautious—exactly the backdrop in which VPA absorption signals often appear.

The Weekly Chart: Classic VPA Hockey Stick and Absorption

On the weekly timeframe, the price action formed a clear hockey-stick pattern. After the sharp fall from the 2025 highs, the decline began to decelerate. Selling pressure that had previously driven wide-range down candles started to lose force. At the lows, we saw the classic VPA absorption signatures that experienced traders watch for:

• High volume appearing on successive narrow-spread candles.
• Small or non-existent lower wicks, indicating that sellers were unable to push price meaningfully lower despite elevated activity.
• Spreads progressively narrowing as the market moved sideways or slightly higher off the bottom.

In VPA terms, this is the footprint of professional money absorbing the supply being offered by weaker hands or forced sellers. The high volume is not distribution; it is accumulation occurring under the cover of residual selling. Once that supply is largely absorbed, the path of least resistance shifts higher. This is precisely the pattern many of us look for repeatedly across markets and timeframes. It requires patience because the absorption phase can last several weeks, but once the move higher begins, it often carries meaningful follow-through. The July 29 earnings release provided the catalyst that helped convert the accumulation into a more visible bullish trend.

July 29 Earnings: The Catalyst

On Wednesday, July 29, 2026, Boston Scientific reported second-quarter results that beat expectations on both the top and bottom lines. Net sales reached $5.442 billion, up 7.5% reported and 7.0% organic—hitting the high end or exceeding prior guidance ranges. Adjusted EPS came in at $0.86, above the $0.82–$0.84 guided range and up solidly from the prior year. Cardiovascular growth was healthy, and international regions (particularly APAC and Latin America) delivered strong performances. The company also highlighted product progress, including clearances and positive clinical data for several platforms, as well as a strategic $1.5 billion investment in MiRus with an option on the TAVR business. Management lowered full-year 2026 guidance once more (organic growth now expected in the 5–6% range and adjusted EPS of $3.28–$3.32). In isolation, that might have been viewed negatively. Yet the combination of a clean beat, evidence of continued execution, and the fact that much of the bad news on growth had already been discounted helped spark the reversal. The stock moved higher from the absorption zone, confirming the VPA read that buying had already been taking place under the surface.

C-Suite and Director Buying: Confidence at the Lows

One of the more encouraging developments has been the cluster of insider purchases by corporate insiders in late July and early August 2026. Most notably:

• CEO and Chairman Michael F. Mahoney purchased roughly 186,000–208,000 shares in early August for approximately $9–10 million at prices around $48.
• Director David C. Habiger made multiple purchases in the first week of August at prices in the $47–$48 range.
• Director Edward J. Ludwig bought shares near the end of July around $45.50.

When the CEO and multiple directors are writing personal checks at levels well below the previous highs—and after a multi-month decline—it is a meaningful signal of internal confidence. These are not token purchases. They occurred in the same price region where the weekly VPA absorption was most evident, reinforcing the idea that informed participants saw value.

Monitoring the Dark Pools

While the weekly chart and public volume have already shown absorption, we continue to monitor dark-pool activity for further confirmation of institutional flow. Dark pools (and other off-exchange venues) often handle large block trades that do not immediately appear in the lit market. Unusual or sustained dark-pool buying at key support levels can precede or accompany the type of accumulation we observed on the weekly candles. In a name like BSX, where institutional ownership is significant, tracking these prints alongside the VPA structure helps distinguish true absorption from temporary pauses in selling. So far, the overall picture remains consistent with professional money building positions during the decelerating phase of the decline.

Patience, Narrowing Spreads, and the Classic Setup

This entire episode is a reminder of two enduring VPA principles. First, markets do not reverse on a single candle; they reverse after supply has been absorbed. The hockey-stick shape—steep decline followed by a flattening base with rising volume on narrowing ranges—is the visual evidence of that process. Second, narrowing spreads on high volume at the lows almost always reveal the true intent of the larger players. Patience is required because the absorption phase can feel protracted, especially after a 50%+ decline that has damaged sentiment. Yet once the catalyst arrives and the move higher begins, the risk/reward for those who waited for confirmation improves markedly.

BSX has now transitioned from a prolonged downtrend into what appears to be the early stages of a more constructive bullish trend on the weekly timeframe. Of course, challenges remain—competition in key categories, the need to re-accelerate growth in WATCHMAN and EP, and the broader market environment. No single pattern guarantees future performance. But from a pure VPA perspective, the combination of clear absorption, an earnings catalyst, and meaningful insider buying has produced a high-quality setup of the type we continuously scan for. For traders and investors who combine volume-price analysis with fundamental catalysts and insider activity, Boston Scientific currently offers a live case study in how patience and careful reading of the tape can identify opportunity after a painful decline.

The narrowing spreads told the story; the subsequent price action is now confirming it. We will continue to monitor the dark pools and the weekly structure for ongoing evidence that the absorption phase has been completed and a more sustained advance is underway.

By Anna Coulling – creator of volume price analysis

By Anna Coulling – creator of volume price analysis